Case Study

Tapestry’s work in healthcare builds trust between stakeholders to address emerging challenges and foster innovation. We create and lead multistakeholder groups that are small and agile, yet equipped to challenge the status quo, supporting the groups’ work with industry knowledge and problem-solving skills.

For example, we had a significant impact on the pace of pharmaceutical innovation in Europe. Formed in 2006, our European Healthcare Innovation Leadership Network (EHILN) engaged stakeholders including pharmaceutical companies, regulators, health technology assessors, payers, patients, and medical experts.  AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, and Johnson & Johnson supported this network, along with Roche and GE.

Among other developments, EHILN led to the design and implementation of a parallel scientific advice process in Europe, where payers and regulators jointly assess the efficacy, and safety drugs as they progress through the development pipeline. The process speeds up development and launch of important therapies.

The network also designed specific working groups to develop disease-specific value frameworks in diabetes and breast cancer. Finally, it addressed many other critical topics pertaining to improving patient outcomes, market access, and health systems improvement and readiness, including an initiative to examine multistakeholder platforms for accelerating the innovation and delivery of Alzheimer’s treatments.

EHILN demonstrated how diverse stakeholders can collaborate to drive large-scale health system improvement.